Equities researchers at Aegis raised their target price on shares of Trius Therapeutics (NASDAQ: TSRX) from $14.00 to $18.00 in a report issued on Monday. The firm currently has a “buy” rating on the stock.
Shares of Trius Therapeutics (NASDAQ: TSRX) traded down 1.97% during mid-day trading on Monday, hitting $6.852. Trius Therapeutics has a 52 week low of $4.41 and a 52 week high of $7.20. The stock’s 50-day moving average is currently $5.81. The company’s market cap is $327.9 million.